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Abstract
Background: Sustained neuroinflammation strongly contributes to the pathogenesis of pain. The clinical challenge
of chronic pain relief led to the identification of molecules such as cytokines, chemokines and more recently matrix
metalloproteinases (MMPs) as putative therapeutic targets. Evidence points to a founder member of the matricial
CCN family, NOV/CCN3, as a modulator of these inflammatory mediators. We thus investigated the possible
involvement of NOV in a preclinical model of persistent inflammatory pain.
Methods: We used the complete Freund’s adjuvant (CFA)-induced model of persistent inflammatory pain and
cultured primary sensory neurons for in vitro experiments. The mRNA expression of NOV and pro-inflammatory
factors were measured with real-time quantitative PCR, CCL2 protein expression was assessed using ELISA, MMP-2
and -9 activities using zymography. The effect of drugs on tactile allodynia was evaluated by the von Frey test.
Results: NOV was expressed in neurons of both dorsal root ganglia (DRG) and dorsal horn of the spinal cord
(DHSC). After intraplantar CFA injection, NOV levels were transiently and persistently down-regulated in the DRG
and DHSC, respectively, occurring at the maintenance phase of pain (15 days). NOV-reduced expression was
restored after treatment of CFA rats with dexamethasone. In vitro, results based on cultured DRG neurons showed
that siRNA-mediated inhibition of NOV enhanced IL-1b- and TNF-a-induced MMP-2, MMP-9 and CCL2 expression
whereas NOV addition inhibited TNF-a-induced MMP-9 expression through b1 integrin engagement. In vivo, the
intrathecal delivery of MMP-9 inhibitor attenuated mechanical allodynia of CFA rats. Importantly, intrathecal
administration of NOV siRNA specifically led to an up-regulation of MMP-9 in the DRG and MMP-2 in the DHSC
concomitant with increased mechanical allodynia. Finally, NOV intrathecal treatment specifically abolished the
induction of MMP-9 in the DRG and, MMP-9 and MMP-2 in the DHSC of CFA rats. This inhibitory effect on MMP is
associated with reduced mechanical allodynia.
Conclusions: This study identifies NOV as a new actor against inflammatory pain through regulation of MMPs thus
uncovering NOV as an attractive candidate for therapeutic improvement in pain relief.
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Background
A growing body of evidence supports the fact that sus-
tained neuroinflammation and particularly the release of
pro-inflammatory cytokines and chemokines (including
TNF-a,I L - 1 b, IL-6 and CCL2) strongly contributes to
the pathogenesis of pain [1-5]. More recently, emerging
studies have established that the extracellular matrix
(ECM) components, particularly matrix metalloprotei-
nases (MMPs) actively participate in the generation and
maintenance of pain thus uncovering new targets for
potential analgesics [6-11]. As a consequence, there is
now a growing interest in the identification of factors
that could modulate these families of molecules. Inter-
estingly, NOV/CCN3, a founder member of the family
of matricellular proteins called CCN (CYR61/CCN1,
CTGF/CCN2, NOV/CCN3), has been involved in the
regulation of cytokines, chemokines and MMP in several
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date for this role.
The nephroblastoma overexpressed gene (NOV) [12]
encodes a secreted cysteine-enriched multimodular pro-
tein that acts as a localized multivalent signal integrator,
primarily mediating its activities through interactions
with specific dimers of integrins [13]. Previous findings
have shown that NOV is highly expressed in the ner-
vous system, especially in the spinal cord and in the
dorsal root ganglion (DRG) during human and murine
development [14-16]. This protein is also detected in
the cerebrospinal fluid [17] and plays a role in the
maturation of granular neuron precursors [18]. How-
ever, its roles in the adult central nervous system remain
elusive. In addition, a relation between NOV and pro-
inflammatory mediators has been reported in several
cell systems. NOV differentially modulates the expres-
sion of MMP-1, -3, -2, -9 and -13 regarding its pro- or
anti-motility effects in a cell-type manner [19-23]. More-
over, in non-nervous cell systems, NOV is regulated by
cytokines (TGF-b,T N F - a and IL-1b) and is able to
modulate their activities exerting anti-fibrotic and anti-
inflammatory effects in a cell-type specific manner
[ 2 4 , 2 5 ] .W eh a v er e c e n t l ys h o w nt h a ti np r i m a r yc u l -
tured astrocytes NOV expression is regulated by the
cytokines TGF-b,T N F - a and IL-1b and that NOV spe-
cifically induces the expression of cytokines (IL-10) and
chemokines (CCL2 and CXCL1) through distinct integ-
rins and signaling mechanisms [25,26]. Altogether, these
findings suggest a potential role for NOV in neuroin-
flammatory processes and led us to investigate the invol-
vement of NOV in the development and persistence of
complete Freund’s adjuvant (CFA)-induced inflamma-
tory pain. Here, in this preclinical model of inflamma-
tory pain, we show that NOV may have an important
function in limiting the deleterious effects of pro-inflam-
matory cytokines particularly on MMP-2 and MMP-9
expression in the nociceptive system, thereby exerting
an anti-nociceptive effect.
Methods
Animals
Male Sprague-Dawley rats (Janvier), weighing 200 to 250
g (5 to 6 weeks of age) at the beginning of the experi-
ments, were used. They were housed four per cage
under standard conditions of light and temperature, for
at least one week before and throughout the whole
experimental period. Commercial chow pellets and tap
water were available ad libitum. Animal-related proce-
dures were approved by the French Ethics Committee in
Animal Experiment (Comité d’Ethique pour l’Expéri-
mentation Animale Charles Darwin, n°Ce5/2010/007)
and carried out according to the French Standard Ethi-
cal Guidelines for Laboratory Animals.
Chemicals and antibodies
Complete Freund’s adjuvant, dexamethasone, collage-
nase, penicillin/streptomycin, transferrin, sodium sele-
nite, putrescin, progesterone, corticosterone,
triiodothyronine, insulin, cytosine arabinoside, proteases
and phosphatases inhibitor cocktails, horseradish peroxi-
dase-conjugated secondary antibodies and rat TNF-a
and IL-1b cytokines were purchased from Sigma-
Aldrich. MMP-9 inhibitor (Inhibitor-I) was purchased
from Calbiochem. Lipofectamine RNAiMax and SiRNAs
were obtained from Qiagen. F-12 nutrient mixture cul-
ture medium with L-glutamine, HBSS, trypsin, horse,
goat and donkey sera and secondary antibodies conju-
gated to Alexa Fluor 488 or 594 were purchased from
Invitrogen.
The primary antibodies used in this study were mouse
anti-glial fibrillary acidic protein (GFAP) and anti-gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) from
Chemicon, goat polyclonal anti-Iba1 (Abcam), mouse
anti-neuronal nuclei (NeuN, Chemicon), mouse anti-
neurofilament 200 (NF200, Sigma-Aldrich), fluorescein
isolectin B4 (IB4, Vector) and guinea pig anti-calcitonin
gene-related peptide (CGRP, Abcys SA, [27]). For NOV
immunochemical detection and western blotting experi-
ments, we used a homemade affinity-purified rabbit
antibody (referred as CT-Mu, anti-mouse NOV anti-
body). This antibody was raised against a peptide speci-
fic to the carboxyl-terminal region of mouse NOV
(amino acids 336 to 354, QNNEAFLQDLELKTSRGEI)
which was coupled to activated keyhole limpet hemo-
cyanin36 and used to generate a rabbit polyclonal anti-
body (CT-Mu). The CT-Mu immunoglobulin G (IgG)
fraction was purified using standard methods on a CT-
Mu peptide affinity column. The flow-through resulting
from CT-Mu purification and containing IgG depleted
from NOV specific IgG was used as a negative control
[26]. Commercial human NOV protein was obtained
from R&D Systems. Recombinant human NOV protein
was produced using a baculovirus expression system in
insect cells and purified as previously described [28].
Drug treatments and experimental design
Inflammatory pain was induced by injecting subcuta-
neously an emulsion of 100 μl of CFA 50% dissolved in
9‰ NaCl (saline) into the left hind paw while the rats
were under brief isoflurane anesthesia. Sham rats
received a 100 μl injection of saline. For characterization
of NOV expression in the CFA model, injured and cor-
responding sham animals (n = 4 rats/group) were sacri-
ficed in the time course experiment at days 1, 3, 5, 7,
14, 21 and 60 after CFA injection. Two independent
experiments were performed.
Water soluble dexamathesone (2 mg/kg i.p. dissolved
in saline) was daily administered for 4 consecutive days
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Page 2 of 20(n = 4 rats/group) starting from day 9 post-CFA or sal-
ine injection. The control groups received four injec-
tions of saline in the same volume. The experiment was
performed twice.
To proceed to small interfering RNA (SiRNA)
intrathecal delivery, control non silencing SiRNA or spe-
c i f i cN O VS i R N A( s e eb e l o w )w e r ep r e p a r e di m m e d i -
ately prior to administration by mixing the RNA
solution (100 μMi na n n e a l i n gb u f f e r )u s i n gt w ot r a n s -
fection reagents, either i-Fect™ in a ratio of 1:4 (w/v)
(Neuromics, [29]) or Transductin™ complex respecting
a molar ratio of 1:10 (IDT, [30]) following manufac-
turers protocols. At these ratios, the final concentration
of RNA as an RNA/lipid or peptide complex was 2 μg
in 10 μl. Ten microliters of NOV siRNA or control
were delivered by intrathecal injection. Injection was
given daily for 3 consecutive days starting from day 3
after CFA or vehicle injection (n = 3 to 4 rats/group)
and tissues were harvested 24 h after the last injection
for RNA analysis.
For behavioral and protein analyses, rats were daily
injected intrathecally under brief isoflurane anesthesia
with 2 μg of NOV siRNA (160 pmoles in i-Fect™ trans-
fection reagent) or control siRNA on the day of CFA
injection and then on the two following days (n = 8
rats/group). To test the NOV effect on pain intensity,
three micrograms of commercial human NOV protein
(in 12.5 μl saline) were delivered for 4 consecutive days,
starting on the 9th day after CFA or saline injection.
Control animals were injected intrathecally with the
same volume of vehicle (n = 8 rats/group). Similarly,
CFA rats were injected with 5 μg of MMP-9 inhibitor or
vehicle (10% DMSO) from day 9 to day 12 post-CFA
injection (n = 6 rats/group). Last intrathecal (i.t) injec-
tion was given 6 hours or 24 hours before animals were
killed. Tissues were used for protein analysis.
Behavioral experiments
After arrival in the laboratory, animals were left to
accustom to the animal care unit for a week. During
the seven days before the experiment, rats were
weighed daily and placed in the test room for one
hour. Mechanical allodynia (painful response to nor-
mally innocuous tactile stimuli) was evaluated the last
two days preceding the scheduled experiment day (-d2
and -d1) as well as before the CFA-injection (d0) and
each day of the experiment. Mechanical allodynia was
measured using calibrated von Frey filaments (Bioseb)
as described by Chaplan [31]. Animals were acclimated
for 20 minutes in inverted individual cages on top of a
wire mesh to provide access to the ventral side of the
hind paws. The von Frey filaments were presented per-
pendicularly to the plantar surface of the selected hind
paw, and then held in this position for approximately 5
seconds with enough force to cause a slight bend in
the filament. A positive response was indicated by an
abrupt withdrawal of the paw. A 50% paw-withdrawal
threshold (PWT) was determined by increasing and
decreasing the intensity and estimated using the Dix-
on’s up-down method [32] that is, 10
(Xf + kΔ)/10 000,
where Xf = the value of the last von Frey filament
employed, k = Dixon value for the p positive/negative
pattern, and Δ = the logarithmic difference between
stimuli. On treatment days, rats were tested prior to
anesthesia followed by i.t administration of drugs. Data
are presented as mean standardized values ± SEM and
were analyzed by analysis of variance (ANOVA) fol-
lowed by the Student-Newman-Keuls’ post hoc test
analysis.
Sacrifice and tissue dissection
Rats were deeply anesthetized with pentobarbital sodium
(150 mg/kg) and perfused transcardially with saline. The
lumbar part of the spinal cord and DRG were removed
and placed in a refrigerated cold plate (0 to 4°C). The
spinal lumbar enlargement (L5-L6) was divided into left
(lesioned side) and right parts by sagittal cut, and then
into their dorsal and ventral ones by a horizontal cut
passing through the ependymal canal. Dorsal quadrants
of spinal cord and DRG were rapidly frozen in liquid
nitrogen then kept at -80°C until being processed for
RNA or protein analysis. Rats used for immunohisto-
chemical study were perfused transcardially with heparin
(1,000 U/ml) in saline followed by 500 ml of a freshly
prepared solution of 4% paraformaldehyde (PAF) in
PBS, pH 7.4. The dissected DRG and lumbar spinal cord
were post-fixed overnight in 4% PAF at 4°C then cryo-
protected in 15% sucrose (24 hours, 4°C) before being
frozen at -40°C in isopentane.
Immunohistochemistry
Fourteen- and twenty-micrometer cryostat sections of
DRG and lumbar spinal cord, respectively, were cut with
a cryostat (Leica CM3050S). Sections were incubated in
a 1X PBS containing 0.1% Triton and 6% serum prior to
incubation with primary antibodies. Primary antibodies
used for this study were CT-Mu anti-NOV murine
(1:5000 for spinal cord, 1:1,000 for DRG), anti-GFAP
(1:800), anti-Iba1 (1:500) to detect glial markers, anti-
NeuN (1:500), anti-NF200 (1:800), fluorescein isolectin
B4 (IB4 1:500) and anti-CGRP (1:800) for neuron detec-
tion. Bound antibodies were detected using secondary
antibodies conjugated to Alexa Fluor 488 or 594. A tyra-
mide signal amplification was used to optimize NOV
detection in spinal cord the following manufacturer’s
protocol (TSA Fluorescein System, PerkinElmer). Sec-
tions were finally mounted in the presence of DAPI to
counterstain nuclei (Vector).
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Thoracic and lumbar DRG were removed from 3
young adult rats and were chemically and mechanically
dissociated into single isolated neurons by enzyme
treatment of 0.125% collagenase for 2 hours, followed
by trypsin and DNAse for 10 minutes at 37°C and by
trituration with Pasteur’s pipette in F-12 medium. The
cell suspension was then passed over a 70 μmf i l t e r ,
centrifuged and the pellet was resuspended in the F-12
nutrient mixture culture medium with L-glutamine
containing 5% horse serum, 1% penicillin/streptomycin,
glucose (4.5 g/l) and supplemented with 1.5% N3 med-
ium (0.1% BSA, 10 mg/ml transferrin, 500 μg/ml insu-
lin, 5.8 μM sodium selenite, 20 μMp u t r e s c i n ,4μM
progesterone, 11 nM corticosterone, 3 μM triiodothyr-
onine, in HBSS). Cells were plated on polylysine-
coated wells (10 μg/ml). Cytosine arabinoside (1 μM)
was added to eliminate mitotic cells including Schwann
cells and fibroblasts. Cultures were maintained at 37°C
in a water-saturated atmosphere with 5% CO2 for 5
days before the experiment. On the fifth day of culture,
neurons exhibited globular cell bodies and extended
axonal processes.
Infection of primary sensory neurons culture with NOV
adenovirus
Viral vectors used were either adenoviral vector contain-
ing the NOV gene under the control of a cytomegalo-
virus promoter (Ad-NOV, 1.1 × 10
11 infectious
particles/ml) kindly provided by Dr C. Haberberger
(Fibrogen Inc) or a control virus (Ad-null, 2.2 × 10
11
infectious particles/ml). Cells were infected with viruses
at the ratio of 500 infectious particles/cell in culture
medium containing 1% horse serum for 2 hours at 37°C.
After 2 hours, media were replaced by serum deprived
medium for an additional 48 hours prior to treatment.
Neither the Ad-NOV nor the mock-infection showed
deleterious cytotoxicity.
SiRNA and in vitro transfections
Specific siRNA targeting NOV, integrins b1, b3 or b5
was used as previously described [26]. A siRNA with a
non-silencing oligonucleoti d es e q u e n c e( c o n t r o l ,C t r )
showing no known homology to mammalian genes was
used as a negative control. Cultured DRG cells were
transfected with siRNA (1.5 μg, 120 pmoles) using
RNAiMax transfection reagent according to the manu-
facturer’s instructions. Forty-eight hours after transfec-
tion, cultures were serum deprived and treated with
cytokines and/or NOV for 6 to 24 hours. Cells were
harvested and subjected to reverse transcription and
real-time PCR. Conditioned media were collected for
immunoblotting and detection of MMP-2 and -9 enzy-
matic activities.
Real-time RT-PCR
Total RNA was extracted from DRG, dorsal horns of
spinal cord or cultured DRG neurons using the
Nucleospin RNA II kit (Macherey-Nagel). Then, first-
strand cDNA was synthesized from 500 ng total RNA
using the High Capacity cDNA Reverse Transcription
kit (Applied Biosystems) according to the manufacturer’s
protocol. Quantitative real-time PCR amplifications were
performed on the ABI 7300 apparatus (Applied Biosys-
tems). The real time PCR amplification mixture (20 μl)
contained 2 μl of 1/10 diluted cDNA template, 10 μlo f
Kit Power SYBR Green Master Mix (Applied Biosys-
tems), 6 μl of nuclease-free water and 2 μlo fp r i m e r
mix (5 μM). Standard curves for target and housekeep-
ing genes were generated by serial dilution. Specific pri-
mers (Sigma-Aldrich) used for amplification of target
genes were designed using the online Primer3 Input
program and verified for specificity on BLAST. Rat pri-
mers sequences are listed below. The comparative Ct
method [33] was used to calculate gene expression
values. The ribosomal S26 was used as a housekeeping
gene.
Substrate gel electrophoresis (zymography)
The gelatinases MMP-2 and MMP-9 proteolytic activ-
ities from rat tissues and from DRG neurons cultured in
serum-deprived medium were detected by zymography.
Conditioned media were centrifuged to remove cell deb-
ris and then stored at -20°C until further analysis. Fro-
zen tissues were homogenized on ice by sonication in
RIPA buffer. Twenty and thirty micrograms of total pro-
teins (from conditioned media and DRG tissues, respec-
tively) were subjected to electrophoresis under non-
reducing conditions in 8% SDS-polyacrylamide gels
copolymerized with 1 mg/ml gelatin. Gels were washed
twice for 30 minutes in 2.5% Triton X-100 to remove
SDS, incubated in substrate buffer (50 mM Tris-HCl, 5
mM CaCl2, 1 μM ZnCl2, 0.01% NaN3, pH 7.5) over-
night at 37°C, stained in 0.5% Coomassie Blue G in 40%
(Continued)
Genes Sense primers Antisense primers
NOV/ccn3 agtcatggtcattggaacctgta ggacaactccttcactatgtttctt
CCL2 ccagaaaccagccaactctc gctacaggcagcaactgtga
IL-6 ttccaatgctctcctaatgga ggtttgccgagtagacctca
IL-1b gcaatggtcgggacatagtt gagacctgacttggcagagg
TNF-a agtccgggcaggtctacttt gggctctgaggagtagacga
Substance P (SP) ggtccgacagtgaccaaatc agttctgcattgcgcttctt
MMP-2 gccaaggtggaaatcagaga atgtcagacaacccgagtcc
MMP-9 cgcaagcctctagagaccac aaccacaggcttggatgtgt
S26 aaggagaaacaacggtcgtg agagcttgggaagcacgtaa
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Page 4 of 20methanol, 10% acetic acid for 30 minutes at room tem-
perature and destained in 40% ethanol, 1% acetic acid.
Clear proteolytic zones indicated the presence of gelati-
nases at their respective molecular weights.
CCL2 measurement
CCL2 concentrations in primary sensory neuron culture
supernatants were quantified by using an ELISA test
(OptEIA ™, BD Biosciences Pharmingen) following the
manufacturer’s instructions. At least two independent
experiments were performed.
Western blotting
Frozen tissues were homogenized on ice by sonication
in lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5
mM sodium pyrophosphate, 1 mM b-glycerophosphate)
(Cell Signaling) supplemented with protease and phos-
phatase inhibitor cocktails. Protein concentration was
determined using the Bradford assay (Bio-rad) with BSA
as the standard. Proteins present in 20 μg of lysates
were analyzed. For the detection of secreted NOV from
primary sensory neuron cultures, protein samples from
conditioned medium were collected after precipitation
by deoxycholate/trichloracetic acid (DOC/TCA). Protein
samples were subjected to electrophoresis in 10% redu-
cing SDS-PAGE before being transferred to polyvinyli-
dene difluouride membranes (Millipore) for
immunological detection. The membrane was incubated
with the CT-Mu mouse anti-NOV polyclonal antibody
diluted to 1:500 for 1 hour at room temperature, fol-
lowed by horseradish peroxidase-conjugated secondary
antibodies. Immunoreactive proteins were detected by
Enhanced chemiluminescence (Amersham, GE
Healthcare).
Statistical analysis
Data are presented as mean values ± SEM and were
analyzed with student t-test (two groups only) or
ANOVA followed by the Student-Newman-Keuls’ post
hoc test analysis. A value of P < 0.05 was considered
statistically significant.
Results
NOV is expressed by neurons of the DRG and dorsal horn
of the spinal cord (DHSC)
NOV immunoreactivity (-IR) in nociceptive structures
was first investigated by immunohistochemistry in the
adult normal rat. In the DRG, NOV-IR was mostly neu-
ronal as it displayed an overlapping pattern with the
neuronal marker NeuN (Figure 1, a-c). NOV-IR was
present in all neurons and was colocalized with both
CGRP
+-peptidergic and IB4
+-non-peptidergic neurons
(Figure 1, d-i) as well as with the large-diameter
neuronal marker NF200 (Figure 1, j-l). NOV-IR could
be detected in both neuronal cell bodies and processes
(Figure 1, m-o).
In the lumbar DHSC, NOV-IR was detected in all
lumbar levels and throughout all laminae (Figure 2A, a).
NOV-IR was associated with the cytoplasm of spinal
neurons of profound laminae and had a characteristic
appearance in the ECM/pericytoplasmic region in the
superficial laminae of the DHSC (Figure 2A, a-d).
NOV-IR showed overlapping staining with CGRP and
NF200 neuronal markers (Figure 2B, a-f). NOV-IR did
not exhibit an overlapping staining with either the
microglial marker Iba1 or the astrocytic marker GFAP
(Figure 2B, g-l). Interestingly, a more moderate NOV-IR
was also present in the dorsolateral funiculus of the
spinal cord (Figure 2A, a asterisk). These data indicate
that NOV is present in nociceptive structures and is
essentially expressed by neurons in the DRG and DHSC.
NOV expression is downregulated in DRG and DHSC at
late stages of CFA-induced inflammatory pain
To identify whether NOV could play a role during the
development of inflammatory pain, we first performed a
time-course analysis of NOV expression in the DRG
and DHSC after either CFA or saline hind paw injec-
tion. From day 1 to 7 after pain induction, no significant
variation of NOV mRNA expression was observed in the
ipsilateral DRG and DHSC (Figure 3A and 3B, and data
not shown). By contrast, in the DRG, NOV mRNA
levels were significantly decreased by 40% at day 15 (**P
< 0.01, n = 6 to 8) and returned to their basal levels
thereafter (Figure 3A). Spinal NOV mRNA expression
was significantly downregulated by 58% starting from
day 15 post-CFA (**P < 0.01, n = 8) and persisted at
low levels for at least 60 days with a 40% decrease (**P
< 0.01, n = 6) (Figure 3B). Consistent with the NOV
mRNA expression pattern, NOV protein quantification
on western blots in the ispilateral DHSC showed a sig-
nificant (*P <0 . 0 5 ,n=5t o6 )d e c r e a s eb y3 4 % ,3 1 %
and 40% at 15, 21 and 60 days post-CFA, respectively
(Figure 3C). No variation of NOV distribution was
observed in this structure in CFA rats compared to
respective shams (data not shown). These results reveal
the fact that, in the time course of CFA-induced pain,
NOV levels are downregulated in the ipsilateral DRG
and DHSC, suggesting a potential functional association
between reduced NOV levels at a late phase and the
establishment of prolonged pain.
Dexamethasone treatment of CFA rat restores NOV
expression in nociceptive structures
We then asked whether the treatment of CFA rats with
the anti-inflammatory and analgesic glucocorticoid dexa-
methasone [34] could impact NOV expression. As
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Page 5 of 20Figure 1 Neuronal expression of NOV in DRG. Immunolocalization using CT-Mu anti-mouse NOV antibody (red, b, e, h, k, n) and antibodies
against neuronal markers NeuN (a), CGRP (g, m), IB4 (d) and NF200 (j). Overlay of the labeling (merge c, f, i, l, o). No primary antibody (control)
and IgG depleted of NOV-specific IgG (flow through, FT) were used as negative controls. Scale: 100 μm.
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Page 6 of 20shown in Figure 4A and 4C, 13 days after CFA-induced
pain, NOV mRNA levels were significantly decreased in
DRG and in DHSC (*P <0 . 0 5 ,n = 4). Dexamethasone
treatment re-established NOV-reduced expression in
ipsilateral DRG and DHSC to levels measured in sham
rats (*P < 0.05, n = 4). Dexamethasone had no signifi-
cant effect on NOV expression in sham rats (Figure 4A
and 4C). We also investigated mRNA expression of the
Figure 2 Neuronal expression of NOV in the dorsal horn of the spinal cord.( A) NOV immunolabeling in dorsal spinal cord laminae and in
the dorsolateral funiculus (a, asterisk). (b-d) Immunolocalization using neuronal NeuN (b) and NOV (c) antibodies, overlay (merge, d). No primary
antibody (control) and IgG depleted of NOV-specific IgG (flow through, FT) were used as negative controls. Scale: 100 μm. (B) Co-
immunostaining using antibodies against NOV (green, b, e, h, k), neuronal (CGRP, a; NF200, d), astrocytic (GFAP, g) and microglial (iba1, j)
markers. Overlay of the labeling (merge c, f, i, l). Scale: 50 μm.
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Page 7 of 20cytokines IL-6, CCL2, IL-1b and TNF-a in saline and
CFA rats ± dexamethasone. Cytokine expression was
significantly upregulated in CFA rats, with a mean of
1.5-fold in the DRG and 3.5-fold in the DHSC com-
pared to respective sham (Figure 4B and 4D, *P < 0.05,
**P < 0.01, n = 4). Dexamethasone had an inhibitory
effect on the induction of IL-6, CCL2, IL-1b and TNF-a
in both DRG and DHSC (Figure 4B and 4D, †P <0 . 0 5 ,
††P < 0.01, n = 4). This finding demonstrates for the
first time in vivo a regulatory effect of dexamethasone
on NOV expression and is in accordance with ex vivo
studies [35]. This result is compatible with a possible
involvement of NOV in inflammatory and/or nocicep-
tive processes.
Endogenous NOV regulates cytokine-induced nociceptive
molecules in primary sensory neurons cultures
To gain insights into the possible role of NOV downre-
gulation in the persistence of inflammatory pain, we car-
ried out experiments based on cultured neurons from
rat DRG. Because of the aforementioned effects of NOV
on the regulation of cytokine, chemokine, and MMP
expression in non-neuronal cell types, we explored the
hypothesis that NOV was involved in such regulation in
cultured DRG neurons. We first assessed the impact of
siRNA-mediated NOV inhibition on the expression of
MMP-9, CCL2, MMP-2 and substance P (SP) in
response to cytokines stimulation.
DRG neuron cultures were transfected with a NOV-
targeted siRNA (SiNOV) or ac o n t r o ls i R N A( C t r )c o n -
taining a non-silencing sequence. SiNOV inhibited more
than 80% of both NOV mRNA and protein expression
at 72 hours (Figure 5A and 5B).
A ss h o w ni nF i g u r e5 Ca n d5 D ,N O Vk n o c k d o w nl e d
to amplified stimulatory effects of the cytokines TNF-a
and IL-1b on the mRNA levels of MMP-9 (siNOV × 73.9
±1 . 6versus C t r×2 7±2 . 2 ;s i N O V×3 1 2±8 . 1 1versus
Ctr × 164 ± 11.5, respectively, †P < 0.05) and CCL2
(siNOV × 31 ± 0.7 versus C t r×1 4±0 . 4 ;s i N O V×2 0±
0.75 versus Ctr × 8 ± 0.58, respectively, †P < 0.05). NOV
depletion also impacted CCL2 expression under basal
conditions (Figure 5D, not treated, NT, †P < 0.05).
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Figure 3 NOV expression in DRG and dorsal horn of spinal cord (DHSC) during CFA-induced pain.( A, B) NOV mRNA expression in DRG
(A) and DHSC (B) ipsilateral to CFA injection in the hind paw. Transcript levels were quantified by RT-qPCR. Values were normalized to rat S26
mRNA levels. The corresponding control of the same time course (sham, sh) was set to 1. Data represent the mean value ± SEM of two
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DHSC. Representative western blot (left panel) and quantification of the protein levels normalized to GAPDH (right panel). Values are reported
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Page 8 of 20As shown in Figure 5E and 5F, under basal condition
(NT), MMP-2 and SP mRNA levels showed significant
increases with a mean of 2-fold when NOV expression
was abrogated (†P < 0.05). These increased MMP-2 and
SP expressions were not amplified upon cytokine expo-
sure (Figure 5E and 5F). Comparable results were
obtained when DRG cultures were exposed to cytokines
for 6 hours (data not shown).
NOV depletion further enhanced cytokine-induced
MMP-9 enzymatic activity with a mean of 1.8-fold (Fig-
ure 6A, †P < 0.05) and CCL2 protein levels with a mean
of 1.6-fold (Figure 6B and 6C, †P < 0.05). NOV knock-
down failed to significantly impact MMP-2 activity (Fig-
ure 6A).
Collectively, these data indicate that the blockade of
e n d o g e n o u sN O Ve x p r e s s i o ni nc u l t u r e dD R Gn e u r o n s
potentiates the induction of specific pro-nociceptive
molecules by cytokines in vitro. Thus NOV deficiency
leads to a greater response of sensory neurons to
inflammatory stimuli thereby participating in the hyper-
sensitization of nociceptors.
NOV inhibits TNF-a-induced MMP-9 in DRG cultures
through b1 integrin
We next focused our interest on MMP-9 modulation by
NOV. We investigated MMP-9 mRNA levels in DRG
neuron cultures exposed to TNF-a (1 ng/ml) for one
hour prior to NOV addition (1 μg/ml) in time-course
experiments. As shown in Figure 7A, addition of NOV
decreased the stimulatory effect of TNF-a on MMP-9
mRNA expression. The NOV inhibitory effect on TNF-
a-induced MMP-9 was rapid and transient since inhibi-
tion peaked at 5 hours with 50% inhibition (***P <
0.001) and declined thereafter. The specificity of this
effect obtained with a home-purified recombinant pro-
tein (Figure 7B, bac, ***P < 0.001) was confirmed by
using commercial human NOV produced in murine cell
line (Figure 7B, mu, **P < 0.01). Similar results were
Sham / saline
CFA / saline
CFA / DEXA
Sham / DEXA
C
AB
DRG
DHSC
DRG
DHSC D
NOV
0
0.2
0.4
0.6
0.8
1
1.2 ns
* *
CFA / saline
CFA / DEXA
NOV
* *
0
0.2
0.4
0.6
0.8
1
1.2 ns
R
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
 
(
f
o
l
d
 
c
h
a
n
g
e
s
)
R
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
 
(
f
o
l
d
 
c
h
a
n
g
e
s
)
R
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
 
(
f
o
l
d
 
c
h
a
n
g
e
s
)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2 ** **
IL-6 CCL2 IL-1ȕ TNF-Į
*
**
††
††
††
†
R
e
l
a
t
i
v
e
 
m
R
N
A
 
l
e
v
e
l
s
 
(
f
o
l
d
 
c
h
a
n
g
e
s
)
IL-6 CCL2
0
1
2
3
4
5
**
**
IL-1ȕ TNF-Į
**
**
6
††
††
††
††
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Figure 5 Effect of NOV knockdown on cytokine-stimulated MMP-2/-9, CCL2 and SP mRNA in DRG neuronal cultures.( A, B) NOV mRNA
(A) and protein expression (B) 72 hours following transfection of primary sensory neurons with a control non-silencing siRNA (Ctr) or a specific
siRNA against NOV (siNOV). NOV mRNA and secreted protein in the conditioned medium were quantified by RT-qPCR and western blot
respectively. (C-F) Experiments were performed 48 hours following transfection with a control (control, Ctr) or a specific NOV siRNA (siNOV).
MMP-9, CCL2, MMP-2 and substance P (SP) mRNA were evaluated by RT-qPCR after a 24 hour-exposure to cytokines TNF-a (1 ng/ml) or IL-1b (1
ng/ml). Data reported are fold changes versus the corresponding control of DRG cultures transfected with control siRNA exposed to normal
medium (not treated, NT) and represent the mean of four values in a representative experiment performed at least two times with similar results
(*P < 0.05 cytokine versus NT. †P < 0.05 siNOV versus Ctr).
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Page 10 of 20obtained with NOV overexpression by infecting DRG
cultures with an adenovirus recombinant for NOV (Ad-
NOV, *P < 0.05) (Figure 7C). Thus, NOV counteracts
the stimulatory action of TNF-a on MMP-9 expression
in primary cultured sensory neurons.
So far, NOV has been shown to interact with the
integrin dimers a5b1, a6b1, avb3 and avb5 and with
Notch receptor [13] and, more recently, to modulate
MMP-13 expression through avb3/avb5 engagement
[23]. Thus, we wondered if NOV inhibitory action on
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Figure 6 Effect of NOV knockdown on cytokine-stimulated MMP-2/-9 activities and CCL2 concentration in DRG neuronal cultures.
Experiments were performed 48 hours following transfection of primary sensory neurons with a control non-silencing siRNA (Ctr) or a specific
NOV siRNA (siNOV). (A) Upper panel, representative gelatin zymograph showing MMP-9 and MMP-2 enzymatic activities after transfection and
treatment for 24 hours with cytokines TNF-a (1 ng/ml) or IL-1b (1 ng/ml). Lower panel, quantification of MMP-9 and MMP-2 gelatinolytic bands.
Data represent the mean of four values ± SEM (ns, not significant, *P < 0.05 cytokine versus not treated (NT), †P < 0.05 siNOV versus Ctr). (B, C)
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Page 11 of 20cytokine-stimulated MMP-9 involved integrin receptors.
Integrin subunits av and b1 were expressed at the high-
est level (av mRNA level was approximately 3-fold
higher than a5 and a6 and, b1 was 50-fold more
expressed than b3 and b5, data not shown). Thus, the
integrins with which NOV interacts are expressed by
cultured sensory neurons. As the b subunits in integrins
are essential for signal transduction [36], we blocked b1,
b3 or b5 expression using a siRNA approach. Cultured
primary sensory neurons transfection with a b1-, b3-o r
b5-specific siRNA resulted in an 88%, 75% and 85%
decrease of b1, b3 and b5 mRNA levels, respectively
(data not shown). While b3 or b5 depletion did not pre-
vent NOV from inhibiting the induction of MMP-9 by
TNF-a (with respective 61% and 39% inhibitions, **P <
0.01, ***P < 0.001), b1 knockdown significantly abolished
this inhibitory effect (Figure 7D). These data indicate
that, in cultured primary sensory neurons, the NOV
inhibitory action on TNF-a-induced MMP-9 expression
requires interaction with integrin b1.
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Figure 7 Effect of NOV treatment on TNF-a-stimulated MMP-9 mRNA expression in DRG neuronal cultures.( A)D R Gc u l t u r e sw e r e
exposed to TNF-a (1 ng/ml) for 1 hour prior to NOV treatment (1 μg/ml). Cells were harvested 2, 5, 8 or 24 hours after NOV treatment. (B) DRG
cultures were exposed to TNF-a (1 ng/ml) for 1 hour prior to NOV treatment (1 μg/ml) for 5 hours with recombinant human NOV protein
produced using a baculovirus expression system in insect cells (bac) or with commercial human NOV protein produced in a murine cell line
(mu). (C) Cells were infected with NOV adenovirus (Ad-NOV) or control virus for 48 hours and then exposed to TNF-a (1 ng/ml) for an additional
12 hours. MMP-9 mRNA expression was evaluated by RT-qPCR. Data reported are fold changes versus the corresponding control of DRG cultures
exposed to normal medium (NT, not treated) and represent the mean of four values in a representative experiment out of two experiments
giving similar results (*P < 0.05, **P < 0.01, ***P < 0.001 TNF-a + NOV versus TNF-a alone). (D) DRG cultures were exposed to TNF-a (1 ng/ml)
for 1 hour prior to NOV treatment (1 μg/ml for 5 hours) 48 hours following transfection with a control non-silencing siRNA (Ctr) or a specific
siRNA against integrin b1, b3 or b5. Values represent the percentage of inhibition ± SEM of MMP-9 by NOV upon TNF-a stimulation compared to
TNF-a exposure of two independent experiments (ns: not significant, *P < 0.05, **P < 0.01, ***P < 0.001 TNF-a + NOV versus TNF-a).
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Page 12 of 20MMP-2 and MMP-9 expression mirrors NOV expression in
CFA-induced inflammatory pain and MMP-9 inhibition
attenuates mechanical allodynia
It has been reported that following nerve injury, MMP-9
is transiently upregulated in injured DRG and partici-
pates in neuropathic pain induction, whereas MMP-2
displays a delayed increase in DRG and DHSC and is
involved in a later phase of neuropathic pain mainte-
nance [10]. So far, no characterization of MMPs expres-
sion in the CFA model of inflammatory pain has been
carried out. Thus, we first examined MMP-2 and MMP-
9 expression patterns in the DRG and DHSC during
CFA-induced inflammatory pain. As shown in Figure
8A and 8B, MMP-9 mRNA levels were transiently upre-
gulated in DRG on days 15 (×3.95 ± 0.55, **P < 0.01, n
= 4) and 21 (×2 ± 0.36, *P < 0.05, n = 4) as well as in
the DHSC 15 days (×2.8 ± 0.6, *P < 0.05, n = 4) after
CFA injection, and returned to levels of sham rats there-
after. Markedly, MMP-2 expression showed no variation
in DRG, but a mean 2-fold persistent upregulation in
DHSC at late stages (×3.45 ± 0.66 on day 15; ×2 ± 0.66
o nd a y2 1a n d×1 . 9 4±0 . 3 6o nd a y6 0p o s t - C F A ,* P <
0.05, n = 4). Moreover, dexamethasone treatment at late
stages of inflammatory pain repressed MMP-2/-9
expression in DRG and DHSC of CFA rats (Figure 8C
and 8D, *P < 0.05, **P <0 . 0 1 ,n=4 ) .T h u s ,t h ei n d u c -
tion of MMP-2 and MMP-9 mirrors reduced NOV
expression at late stages in the establishment of inflam-
matory pain (Figure 3A and 3B).
In an acute model of inflammatory pain, carrageenan-
induced mechanical allodynia is partially prevented in
MMP-9-null mice [[10], suppl. data]. To test whether
MMP-9 could impact CFA-induced persistent inflamma-
tory pain, the mechanical allodynia of CFA rats treated
with an MMP-9 inhibitor (MMP-9i) was evaluated using
the von Frey filament test. As shown in Figure 8E,
repeated intrathecal injections of MMP-9 inhibitor from
day 9 to day 12 post-CFA injection significantly attenu-
ated mechanical allodynia (5.5 ± 0.8 g in CFA rats trea-
ted with MMP-9i compared to 2.7 ± 0.3 g in CFA rats
injected with vehicle, **P < 0.01, n = 6). Altogether,
these data suggest a role for MMP-9 in the maintenance
of CFA-induced inflammatory pain.
Endogenous NOV knockdown upregulates MMP-2 and
MMP-9 in vivo and increases mechanical allodynia of CFA
rats
We further investigated whether inhibition of NOV
endogenous expression could modulate MMPs expres-
sion in vivo.A ss h o w ni nF i g u r e9 A ,t h ei n t r a t h e c a l
administration of NOV siRNA (siNOV) at early stages
of CFA-induced pain (when neither NOV nor MMPs
endogenous expressions are altered) resulted in a 40%
inhibition of NOV mRNA expression in the DRG (data
not shown) and a 58% reduction of NOV protein
expression in the DHSC, compared with control siRNA-
treated rats (**P < 0.01, n = 6). NOV downregulation
led to a significant increase of MMP-9 mRNA levels in
DRG of CFA rats (×1.43 ± 0.08, *P < 0.05, n = 6) with-
out affecting MMP-2 expression (Figure 9B). Conversely,
in DHSC, where MMP-9 mRNA levels showed no sig-
nificant variation when NOV was inhibited, MMP-2
mRNA levels were significantly upregulated (×2 ± 0.17,
**P < 0.01, n = 6) (Figure 9C). Consistent with NOV
knockdown effects on MMPs mRNA in DRG, NOV
siRNA delivery specifically increased MMP-9 proteolytic
activity (x 1.59 ± 0.10 **P < 0.01, n = 6) and had no
effect on MMP-2 activity in CFA rat DRG (Figure 9D).
Due to lower MMP-2 and MMP-9 expressions in DHSC
compared to DRG (5-fold and 2-fold less mRNA,
respectively, data not shown), their gelatinase activities
were below the detection threshold. Thus, in CFA-
induced pain, NOV downregulation specifically affects
MMP-9 and MMP-2 expressions in DRG and spinal
cord, respectively.
In order to test whether endogenously produced NOV
could modulate inflammatory pain, we evaluated the
mechanical allodynia of CFA rats treated with NOV. As
s h o w ni nF i g u r e9 E ,i n t r a t h e c a ld e l i v e r yo fs i N O V
resulted in a significant increase of mechanical allodynia
compared to rats injected with control siRNA (*P <
0.05, n = 8). These data strongly suggest that endogen-
ously produced NOV influences pain intensity and
further support the hypothesis that NOV downregula-
tion could participate in pain processes through upregu-
lation of MMP-2 and MMP-9.
NOV treatment of CFA rats inhibits MMPs and reduces
mechanical allodynia
We then wondered if NOV treatment of CFA rats at
later stages had an impact on MMPs expression and
nociceptive thresholds. To this aim, rats were intrathe-
cally injected with NOV protein (3 μg) for 4 consecutive
days starting from day 9 after CFA or saline injection.
In accordance with MMPs pattern of expression in the
CFA-induced pain model, as s h o w ni nF i g u r e1 0 Aa n d
10B, MMP-9 was upregulated both in the DRG and
DHSC of CFA rats compared to sham animals, while
MMP-2 was only significantly increased in DHSC. NOV
treatment significantly abolished MMP-9 upregulation
in ipsilateral DRG and DHSC (*P <0 . 0 5 ,n=4t o5 ) .
Notably, NOV treatment resulted in significant inhibi-
tion of MMP-2 induction in DHSC (*P < 0.05, n = 4 to
5) and had no impact on its expression in DRG (Figure
10A and 10B). NOV administration to sham rats had no
effect on MMPs expression. Consistent with NOV
action on MMPs mRNA in DRG, NOV treatment speci-
fically reduced MMP-9 proteolytic activity and had no
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Figure 8 MMP-2/-9 expression after CFA injection and the effect of MMP-9 inhibition on CFA-induced mechanical allodynia.( A, B)
Levels of MMP-9 and MMP-2 mRNA in the ipsilateral DRG (A) and DHSC, (B) after CFA or vehicle (sham) injection (*P < 0.05, **P < 0.01 CFA
versus corresponding sham, n = 4). (C, D) Dexamethasone (DEXA, 2 mg/kg i.p) or vehicle (saline) were daily administered for 4 consecutive days
to sham or CFA rats, starting from day 9 after CFA or saline injection into the paw. Transcript levels were quantified by RT-qPCR. Values were
normalized to rat S26 mRNA levels and reported to the control group sham/saline set at 1 (dotted line). The data represent the mean ± SEM of
4 rats per group (*P < 0.05, **P < 0.01 CFA/saline versus CFA/DEXA). (E) MMP-9 inhibitor (MMP-9i, 5 μg) or vehicle (10% DMSO) were intrathecally
(i.t) injected daily for 4 consecutive days starting from day 9 after CFA injection. The paw withdrawal threshold (g) was evaluated using the von
Frey test. Data represent the mean ± SEM of six rats per group (**P < 0.01 MMP-9i- versus vehicle-treated rats).
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Figure 9 Effect of in vivo endogenous NOV inhibition on MMP-2/-9 expression and mechanical allodynia. In CFA rats, NOV-specific siRNA
(2 μg) or control non-silencing siRNA (Ctr) were delivered intrathecally (i.t) daily for 3 consecutive days. (A) NOV protein levels in DHSC.
Representative western blot (left panel) and quantification of protein levels normalized to GAPDH (right panel) (**P < 0.01, siNOV versus Ctr, n =
6) (B, C) Levels of MMP-9 and MMP-2 mRNA in DRG (B) and DHSC. (C) Transcript levels were quantified by RT-qPCR and values were normalized
to rat S26 mRNA level. Data represent the mean value ± SEM of two independent experiments realized with three rats per condition (*P < 0.05
siNOV versus Ctr). (D) Representative gelatin zymograph showing MMP-9 and MMP-2 activities in DRG (left panel) and quantification of MMP-2
and MMP-9 gelatinolytic bands (right panel). Data represent the mean ± SEM of six rats per group (**P < 0.01 siNOV versus Ctr). (E) Paw
withdrawal threshold (g) of CFA rats intrathecally injected with NOV-specific siRNA or control siRNA evaluated using the von Frey test. Data
represent the mean ± SEM of eight rats per group (*P < 0.05 siNOV- versus Ctr-treated rats), BL: baseline.
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Figure 10 Effect of NOV treatment of sham and CFA rats on MMP-2/-9 expression and mechanical allodynia.N O V( 3μg/rat) was
administrated daily by a single intrathecal injection (i.t) for 4 consecutive days starting from the 9th day after CFA injection. (A, B) Levels of
MMP-2 and MMP-9 mRNA in the DRG (A) and DHSC (B) following intrathecal (i.t) treatment with NOV protein or vehicle (*P < 0.05 NOV- versus
saline-treated CFA rats, n = 4 to 5). (C) Representative gelatin zymograph showing MMP-9 and MMP-2 activities (left panels) and quantification of
MMP-2 and MMP-9 gelatinolytic bands (right panels). Data represent the mean ± SEM of three to four rats per group (*P < 0.05 NOV- versus
saline-treated CFA rats). (D) The paw withdrawal threshold (g) was evaluated using the von Frey test. Data represent the mean ± SEM of eight
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*P < 0.05, n = 3 to 4). MMP-2 and -9 gelatinase activ-
ities were below the detection threshold in DHSC. Thus,
in vivo NOV abolishes MMP-2 induction in the dorsal
spinal cord and suppresses MMP-9 upregulation in both
DRG and DHSC.
We tested whether concomitant with inhibition of
MMPs, exogenous NOV could modulate persistent
inflammatory pain. As shown in Figure 10D, CFA injec-
tion produced long-lasting mechanical stimulation
hypersensitivity as reflected by the drastic decrease of
withdrawal threshold to von Frey hairs dropping from
13 ± 0.5 g before CFA injection to 3.6 ± 0.3 g at day 9
post-CFA. Importantly, NOV treatment significantly
attenuated the tactile allodynia developed in CFA rats
(*P <0 . 0 5 ,* * P < 0.01, n = 8) and had no effect on basal
pain perception in sham animals. These findings show
NOV as an anti-allodynic molecule that is able to
reduce established mechanical allodynia in the persistent
phase of inflammatory pain and further suggest that
NOV could exert its anti-allodynic effect through down-
regulation of MMP-2 and MMP-9.
Discussion
Our study identifies NOV as a novel regulator of MMP-
2 and MMP-9 expression in DRG and spinal cord dur-
ing inflammatory pain processes and as an anti-allodynic
molecule. To our knowledge, this is the first evidence
for a function of NOV (or any members of the CCN
family) in a pathophysiological inflammatory process
implicating the nervous system and, particularly, pain
pathogenesis.
We first explored the localization of NOV in nocicep-
tive structures. Whereas NOV has been detected in neu-
rons and astrocytes in the cortex [26], it was mostly
expressed by neurons in the DRG and DHSC in the
adult rat. Immunoreactivity was clearly present in a
fibrillar pattern within DRG nerve axons and in the dor-
solateral funiculus that contains major descending path-
ways, suggesting that spinal NOV could originate partly
from its intrinsic expression in the spinal cord and from
DRG and supraspinal structures axonal transport. These
findings are in accordance with the expression pattern
established previously in rat and human developing
embryos [14-16] and represent the first description of
NOV distribution within the DRG and DHSC in the
adult rat.
We then wondered whether NOV was regulated dur-
ing the establishment of prolonged inflammatory pain.
Indeed, NOV was downregulated in DRG and DHSC in
a time-dependent manner at a late phase of CFA-
induced pain. Moreover, treatment of CFA rats with
dexamethasone could restore NOV expression in both
structures while decreasing the induced pro-
inflammatory genes IL-6, CCL2, TNF-a,I L 1 - b,M M P - 2
and MMP-9. These data further reinforce the hypothesis
of a potential role for NOV in inflammatory and/or
nociceptive processes.
We then investigated in vitro the possible involvement
of NOV in neuroinflammatory processes. An extensive
body of evidence has shown that the pro-inflammatory
cytokines IL-1b and TNF-a, which, we confirmed, are
upregulated at late times of CFA-induced pain, play cri-
tical roles in the generation and maintenance of pain
[1,37]. Since NOV modulates the expression or activity
of cytokines in several cell systems [25], we explored the
involvement of NOV in such regulation in primary cul-
tured sensory neurons. We found that inhibition of
NOV endogenous expression enhances basal and cyto-
kine-induced expression of the pro-nociceptive molecule
CCL2. NOV action on CCL2 appears highly cell-type
dependent since blockade of NOV in primary astrocytes
leads to a reduced basal expression and release of CCL2
[26].
As previously reported, emerging studies point to the
MMP family, especially the two gelatinases MMP-2 and
MMP-9, as key upregulated pro-inflammatory mediators
in a variety of CNS pathologies [38], including pain pro-
cesses [8-11]. Herein, we present the first report of a sti-
mulatory effect of NOV depletion on MMP-9. We also
highlighted NOV as the first CCN member that inhibits
TNF-a-induced MMP-9 expression in primary cultured
sensory neurons. Such an inhibitory effect of NOV on
MMP-9 expression is consistent with previous studies
showing that NOV overexpression in Ewing’s sarcoma
and melanoma cells leads to repression of MMP-9
[21,22]. It appears that NOV, in concert with TNF-a,
exerts differential effects depending on the cell-type.
Indeed, NOV synergizes the inducer effect of TNF-a on
CXCL1 expression in primary astrocytes or enables
TNF-a to induce fibroblast apoptosis whereas it antago-
nizes the stimulatory action of TNF-a on the VCAM
and ICAM adhesion molecules involved in endothelial
inflammation [24,25,39,40]. The extent of NOV-
mediated inhibition of MMP-9 expression in DRG neu-
ron cultures upon TNF-a stimulation is similar to that
reported on VCAM and ICAM in endothelial cells [24].
Recently, NOV has been shown to modulate MMP-13
through avb3/avb5 engagement and further activation of
FAK, PI3K, Akt and NF-B signaling pathways [23].
Here we demonstrate that in cultured sensory neurons,
NOV regulation of cytokine-induced MMP-9 expression
requires the engagement of integrin b1 subunit. Integ-
rins mediate bidirectional transmembrane signaling
between the ECM and intracellular second messengers
[41]. Studies have shown that the engagement of integ-
rin receptor b1 contributes to both neuropathic and che-
mically-induced pains [42-44], thus contrasting with our
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integrin b1 activation to favor or oppose cellular func-
tion depends both on the neuronal state and the precise
molecular environment it encounters [45,46]. Moreover,
the nature of the association between b1 and a integrin
subunits plays an important role in pain hypersensitivity
regarding nociceptive stimuli and specific second mes-
senger cascades [47]. Thus, the effect of integrin b1 acti-
vation could have widely varying effects in cultured
neurons. The intracellular mechanisms involved in NOV
inhibitory action on cytokine-induced MMP-9 in this
system remain to be elucidated.
While a pathophysiological role of MMP-2 and MMP-
9 has been demonstrated in neuropathic pain, the rele-
vance of these metalloproteinases in chronic inflamma-
tory pain is still elusive. Our results show for the first
time that inhibition of MMP-9 significantly decreases
CFA-induced mechanical allodynia. Interestingly,
intrathecal treatment with synthetic MMP-9 inhibitor
has turned out to be more effective in reducing spinal
nerve ligation-induced mechanical allodynia when con-
tinuously infused via an osmotic pump than when admi-
nistered by repeated injections [10]. This suggests that
the MMP-9 inhibitor partial effect on ipsilateral allody-
nia might be improved upon continuous delivery.
Furthermore, since MMP-2 expression is increased in
DHSC as well, it is plausible that pharmacological treat-
ment of CFA rats with a combination of MMP-2 and
MMP-9 inhibitors could exert a more potent anti-allo-
dynic effect than when administered alone.
Next, we showed that NOV regulates MMP-2 and
MMP-9 in vivo and that these regulations are associated
with altered pain intensity. In CFA rats, the siRNA-
mediated knockdown of NOV led to a specific upregula-
tion of MMP-9 in the DRG and MMP-2 in the DHSC
(and CCL2 in the DRG, data not shown), consistent
with our in vitro data. Remarkably, endogenously pro-
duced NOV depletion resulted in increased tactile
hypersensitivity. The compatible pattern of MMP-2/-9
and NOV expression at the late phase of inflammatory
pain further raises the possibility that NOV reduction
could specifically lead to transient MMP-9 induction in
the DRG and a persistent increase of MMP-2 expression
in the spinal cord, thereby contributing to the mainte-
nance of pain. Admittedly, NOV is likely to act in con-
cert with other specific partners of a given
neuroinflammatory environment to modulate MMP-2/-9
expression. This is supported by our data showing NOV
modulation of cytokine activities in vitro and cytokines
induction at a late phase of inflammatory pain. In addi-
tion, NOV reduction at a late phase of the development
of inflammatory pain contrasts with the early develop-
ment of pain hypersensitivity indicating that NOV
might not be involved in the early stage of pain
induction but be required at a later precise time slot
during pain pathogenesis. Even though the NOV-null
mouse has been generated recently, its nervous system
phenotype has not yet been reported. The NOV-null
mouse shows normal development but enhanced neoin-
timal hyperplasia in response to endothelial injury [48].
Our data thus reinforce the idea that NOV is highly
important in tissue homeostasis especially in case of
injury [24] and further highlight the interest of investi-
gating pain symptoms in NOV-null mice. These findings
indicate that endogenous NOV may have an important
function in limiting the deleterious effects of pro-inflam-
matory cytokines particularly on MMPs expression in
the nociceptive system.
Markedly, NOV intrathecal treatment abolished CFA-
induced MMP-9 expression in both DRG and DHSC,
whereas it abrogated MMP-2 induction in DHSC, con-
comitant with decreased CFA-induced ipsilateral allody-
nia. The NOV effect was partial but similar to that
reported for drugs targeting blockade of NF-B, JNK,
IL-1b or TNF-a activities, which partially decrease pain
hypersensitivity after CFA injection but fail to induce
full recovery from pain symptoms [49,50]. Although the
detailed molecular mechanisms involved in the NOV
effect remain to be fully understood, these data reinforce
the hypothesis that NOV exerts an anti-allodynic effect
through modulation of MMP-2 and MMP-9. It is note-
worthy that NOV treatment is able to reduce allodynia
long after CFA administration, when pain symptoms
remain robust. This is of clinical interest since studies
have yielded debatable results revealing limited efficacies
or even ineffectiveness of classical analgesics on
mechanical hypersensitivity when administrated in post-
CFA treatment [51-54]. More importantly, the cure of
chronic inflammatory pain remains partial [55].
Conclusions
Altogether, our findings reveal a role for NOV in the
modulation of CFA-induced pain by exerting anti-
inflammatory and anti-allodynic effects. Our study pro-
vides for the first time evidence that, besides their
recently demonstrated roles in the pathogenesis of neu-
ropathic pain, MMP-2/-9 could be involved in chronic
inflammatory pain as well. We hypothesize that, during
chronic inflammation, NOV downregulation in DRG
and spinal cord contributes to MMP-2/-9 induction
thereby participating in the maintenance of pain inten-
sity. Because NOV appears as a novel mediator in the
functional interplay between cytokine and MMPs in
pain processes, it may alone or in concert with other
drugs represent a new interesting analgesic. Knowing
that recent evidence renders MMP-2/-9 useful targets
for neuropathic pain relief [56], the investigation of
NOV involvement in neuropathic pain would be
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laboratory in this matter appear promising. Nevertheless
further comprehensive research is needed to investigate
the precise mechanisms involved in such function in
order to improve therapeutic solutions.
Abbreviations
CFA: complete Freund’s adjuvant; CCN: cysteine rich 61/connective tissue
growth factor/nephroblastoma overexpressed; DRG: dorsal root ganglia;
DHSC: dorsal horn of the spinal cord; ECM: extracellular matrix; IL-1β:
interleukin-1β; MMP: matrix metalloproteinase; NOV: nephroblastoma
overexpressed; TNF- α: tumor necrosis factor-α.
Acknowledgements
This work was supported by the Institut National de la Santé et de la
Recherche Médicale (INSERM), Institut National du Cancer (INCA) and
Groupement des Entreprises Françaises dans la Lutte contre le Cancer
(GEFLUC). L. Kular was recipient of a doctoral fellowship from the French
Ministère de l’Education Nationale de la Recherche et de la Technologie and
a grant from the ARTHRITIS Fondation Courtin. We thank the vector core of
the University Hospital of Nantes supported by the Association contre les
Myopathies (AFM) for providing the stock of Adeno-CMV-NOV and Adeno-
CMV-null viruses. We are indebted to the skillful assistance of C. Kazazian.
We are grateful to L. Martinerie for critical reading of the manuscript.
Author details
1INSERM UMR_S 938, Centre de Recherche de Saint-Antoine, Hôpital Saint-
Antoine, Paris F-75012, France.
2INSERM UMR_S 975; CNRS UMR 7225, Centre
de Recherche de l’Institut du Cerveau et de la Moelle Epinière, Hôpital Pitié-
Salpêtrière, Paris F-75013, France.
3INSERM UMR_S 702, Hôpital Tenon, 4 rue
de la Chine, 75970 Paris cedex 20, France.
4Université Pierre et Marie Curie 6,
Paris, France.
5Department of Anesthesiology and Pain Medicine, Health
Sciences RR415, 1959 NE Pacific Street, Seattle, WA, USA.
Authors’ contributions
CM and SMP conceived, designed and supervised the study; LK participated
in designing experiments, conducted experiments and prepared the
manuscript. CR, BL, CC, ML and MP performed experiments and revised the
manuscript. PK participated in drafting and revising the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 20 September 2011 Accepted: 21 February 2012
Published: 21 February 2012
References
1. Uceyler N, Schafers M, Sommer C: Mode of action of cytokines on
nociceptive neurons. Exp Brain Res 2009, 196:67-78.
2. Miller RJ, Jung H, Bhangoo SK, White FA: Cytokine and chemokine
regulation of sensory neuron function. Handb Exp Pharmacol 2009,
194:417-449.
3. Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S,
White FA: Chemokines and pain mechanisms. Brain Res Rev 2009,
60:125-134.
4. Kawasaki Y, Zhang L, Cheng JK, Ji RR: Cytokine mechanisms of central
sensitization: distinct and overlapping role of interleukin-1beta,
interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and
neuronal activity in the superficial spinal cord. J Neurosci 2008,
28:5189-5194.
5. Van Steenwinckel J, Reaux-Le Goazigo A, Pommier B, Mauborgne A,
Dansereau MA, Kitabgi P, Sarret P, Pohl M, Melik Parsadaniantz S: CCL2
released from neuronal synaptic vesicles in the spinal cord is a major
mediator of local inflammation and pain after peripheral nerve injury. J
Neurosci 2011, 31:5865-5875.
6. Shubayev VI, Myers RR: Upregulation and interaction of TNFalpha and
gelatinases A and B in painful peripheral nerve injury. Brain Res 2000,
855:83-89.
7. Komori K, Nonaka T, Okada A, Kinoh H, Hayashita-Kinoh H, Yoshida N,
Yana I, Seiki M: Absence of mechanical allodynia and Abeta-fiber
sprouting after sciatic nerve injury in mice lacking membrane-type 5
matrix metalloproteinase. FEBS Lett 2004, 557:125-128.
8. Chattopadhyay S, Myers RR, Janes J, Shubayev V: Cytokine regulation of
MMP-9 in peripheral glia: implications for pathological processes and
pain in injured nerve. Brain Behav Immun 2007, 21:561-568.
9. Kobayashi H, Chattopadhyay S, Kato K, Dolkas J, Kikuchi S, Myers RR,
Shubayev VI: MMPs initiate Schwann cell-mediated MBP degradation and
mechanical nociception after nerve damage. Mol Cell Neurosci 2008,
39:619-627.
10. Kawasaki Y, Xu ZZ, Wang X, Park JY, Zhuang ZY, Tan PH, Gao YJ, Roy K,
Corfas G, Lo EH, Ji RR: Distinct roles of matrix metalloproteases in the
early- and late-phase development of neuropathic pain. Nat Med 2008,
14:331-336.
11. Liu WT, Han Y, Liu YP, Song AA, Barnes B, Song XJ: Spinal matrix
metalloproteinase-9 contributes to physical dependence on morphine in
mice. J Neurosci 2010, 30:7613-7623.
12. Joliot V, Martinerie C, Dambrine G, Plassiart G, Brisac M, Crochet J, Perbal B:
Proviral rearrangements and overexpression of a new cellular gene
(nov) in myeloblastosis-associated virus type 1-induced
nephroblastomas. Mol Cell Biol 1992, 12:10-21.
13. Chen CC, Lau LF: Functions and mechanisms of action of CCN
matricellular proteins. Int J Biochem Cell Biol 2009, 41:771-783.
14. Albrecht C, von Der Kammer H, Mayhaus M, Klaudiny J, Schweizer M,
Nitsch RM: Muscarinic acetylcholine receptors induce the expression of
the immediate early growth regulatory gene CYR61. J Biol Chem 2000,
275:28929-28936.
15. Su BY, Cai WQ, Zhang CG, Martinez V, Lombet A, Perbal B: The expression
of ccn3 (nov) RNA and protein in the rat central nervous system is
developmentally regulated. Mol Pathol 2001, 54:184-191.
16. Kocialkowski S, Yeger H, Kingdom J, Perbal B, Schofield PN: Expression of
the human NOV gene in first trimester fetal tissues. Anat Embryol (Berl)
2001, 203:417-427.
17. Thibout H, Martinerie C, Creminon C, Godeau F, Boudou P, Le Bouc Y,
Laurent M: Characterization of human NOV in biological fluids: an
enzyme immunoassay for the quantification of human NOV in sera from
patients with diseases of the adrenal gland and of the nervous system. J
Clin Endocrinol Metab 2003, 88:327-336.
18. Le Dreau G, Nicot A, Benard M, Thibout H, Vaudry D, Martinerie C,
Laurent M: NOV/CCN3 promotes maturation of cerebellar granule neuron
precursors. Mol Cell Neurosci 2010, 43:60-71.
19. Lin CG, Chen CC, Leu SJ, Grzeszkiewicz TM, Lau LF: Integrin-dependent
functions of the angiogenic inducer NOV (CCN3): implication in wound
healing. J Biol Chem 2005, 280:8229-8237.
20. Laurent M, Martinerie C, Thibout H, Hoffman M, Verrecchia F, Le Bouc Y,
Mauviel A, Kleinman H: NOVH increases MMP3 expression and cell
migration in glioblastoma cells via a PDGFR-alpha-dependent
mechanism. FASEB J 2003, 17:1919-1921.
21. Benini S, Perbal B, Zambelli D, Colombo MP, Manara MC, Serra M,
Parenza M, Martinez V, Picci P, Scotlandi K: In Ewing’s sarcoma CCN3(NOV)
inhibits proliferation while promoting migration and invasion of the
same cell type. Oncogene 2005, 24:4349-4361.
22. Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I,
Elder DE, Perbal B, Herlyn M: Downregulation of CCN3 expression as a
potential mechanism for melanoma progression. Oncogene 2008,
27:2552-2560.
23. Tzeng HE, Chen JC, Tsai CH, Kuo CC, Hsu HC, Hwang WL, Fong YC,
Tang CH: CCN3 increases cell motility and MMP-13 expression in human
chondrosarcoma through integrin dependent pathway. J Cell Physiol
2011, 226:3181-3189.
24. Lin Z, Natesan V, Shi H, Hamik A, Kawanami D, Hao C, Mahabaleshwar GH,
Wang W, Jin ZG, Atkins GB, Firth SM, Rittié L, Perbal B, Jain MK: A novel
role of CCN3 in regulating endothelial inflammation. J Cell Commun
Signal 2010, 4:141-153.
25. Kular L, Pakradouni J, Kitabgi P, Laurent M, Martinerie C: The CCN family: A
new class of inflammation modulators? Biochimie 2011, 93:377-388.
Kular et al. Journal of Neuroinflammation 2012, 9:36
http://www.jneuroinflammation.com/content/9/1/36
Page 19 of 2026. Le Dreau G, Kular L, Nicot AB, Calmel C, Melik-Parsadaniantz S, Kitabgi P,
Laurent M, Martinerie C: NOV/CCN3 upregulates CCL2 and CXCL1
expression in astrocytes through beta1 and beta5 integrins. Glia 2010,
58:1510-1521.
27. Dansereau MA, Gosselin RD, Pohl M, Pommier B, Mechighel P,
Mauborgne A, Rostene W, Kitabgi P, Beaudet N, Sarret P, Melik-
Parsadaniantz S: Spinal CCL2 pronociceptive action is no longer effective
in CCR2 receptor antagonist-treated rats. J Neurochem 2008, 106:757-769.
28. Doghman M, Arhatte M, Thibout H, Rodrigues G, De Moura J, Grosso S,
West AN, Laurent M, Mas JC, Bongain A, Zambetti GP, Figueiredo BC,
Auberger P, Martinerie C, Lalli E: Nephroblastoma overexpressed/cysteine-
rich protein 61/connective tissue growth factor/nephroblastoma
overexpressed gene-3 (NOV/CCN3), a selective adrenocortical cell
proapoptotic factor, is down-regulated in childhood adrenocortical
tumors. J Clin Endocrinol Metab 2007, 92:3253-3260.
29. Luo MC, Zhang DQ, Ma SW, Huang YY, Shuster SJ, Porreca F, Lai J: An
efficient intrathecal delivery of small interfering RNA to the spinal cord
and peripheral neurons. Mol Pain 2005, 1:29.
30. Eguchi A, Meade BR, Chang YC, Fredrickson CT, Willert K, Puri N, Dowdy SF:
Efficient siRNA delivery into primary cells by a peptide transduction
domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009,
27:567-571.
31. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative
assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994,
53:55-63.
32. Dixon WJ: Efficient analysis of experimental observations. Annu Rev
Pharmacol Toxicol 1980, 20:441-462.
33. Pfaffl MW: A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res 2001, 29:e45.
34. Lam FF, Ng ES: Substance P and glutamate receptor antagonists improve
the anti-arthritic actions of dexamethasone in rats. Br J Pharmacol 2010,
159:958-969.
35. Liu C, Liu XJ, Crowe PD, Kelner GS, Fan J, Barry G, Manu F, Ling N, De
Souza EB, Maki RA: Nephroblastoma overexpressed gene (NOV) codes for
a growth factor that induces protein tyrosine phosphorylation. Gene
1999, 238:471-478.
36. Calderwood DA: Integrin activation. J Cell Sci 2004, 117:657-666.
37. Raghavendra V, Tanga FY, DeLeo JA: Complete Freunds adjuvant-induced
peripheral inflammation evokes glial activation and proinflammatory
cytokine expression in the CNS. Eur J Neurosci 2004, 20:467-473.
38. Rosenberg GA: Matrix metalloproteinases in neuroinflammation. Glia
2002, 39:279-291.
39. Chen CC, Young JL, Monzon RI, Chen N, Todorovic V, Lau LF: Cytotoxicity
of TNFalpha is regulated by integrin-mediated matrix signaling. EMBO J
2007, 26:1257-1267.
40. Chen CC, Lau LF: Deadly liaisons: fatal attraction between CCN
matricellular proteins and the tumor necrosis factor family of cytokines.
J Cell Commun Signal 2010, 4:63-69.
41. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 2002,
110:673-687.
42. Dina OA, Parada CA, Yeh J, Chen X, McCarter GC, Levine JD: Integrin
signaling in inflammatory and neuropathic pain in the rat. Eur J Neurosci
2004, 19:634-642.
43. Fu WM, Chang TK, Sun WZ, Ling QD, Peng HC, Liou HC, Lu DY, Huang TF:
Inhibition of neuropathic pain by a potent disintegrin-triflavin. Neurosci
Lett 2004, 368:263-268.
44. Tsuda M, Toyomitsu E, Komatsu T, Masuda T, Kunifusa E, Nasu-Tada K,
Koizumi S, Yamamoto K, Ando J, Inoue K: Fibronectin/integrin system is
involved in P2X(4) receptor upregulation in the spinal cord and
neuropathic pain after nerve injury. Glia 2008, 56:579-585.
45. Lemons ML, Condic ML: Combined integrin activation and intracellular
cAMP cause Rho GTPase dependent growth cone collapse on laminin-1.
Exp Neurol 2006, 202:324-335.
46. Lemons ML, Condic ML: Integrin signaling is integral to regeneration. Exp
Neurol 2008, 209:343-352.
47. Dina OA, Hucho T, Yeh J, Malik-Hall M, Reichling DB, Levine JD: Primary
afferent second messenger cascades interact with specific integrin
subunits in producing inflammatory hyperalgesia. Pain 2005, 115:191-203.
48. Shimoyama T, Hiraoka S, Takemoto M, Koshizaka M, Tokuyama H,
Tokuyama T, Watanabe A, Fujimoto M, Kawamura H, Sato S, Tsurutani Y,
Saito Y, Perbal B, Koseki H, Yokote K: CCN3 inhibits neointimal hyperplasia
through modulation of smooth muscle cell growth and migration.
Arterioscler Thromb Vasc Biol 2010, 30:675-682.
49. Narita M, Shimamura M, Imai S, Kubota C, Yajima Y, Takagi T, Shiokawa M,
Inoue T, Suzuki M, Suzuki T: Role of interleukin-1beta and tumor necrosis
factor-alpha-dependent expression of cyclooxygenase-2 mRNA in
thermal hyperalgesia induced by chronic inflammation in mice.
Neuroscience 2008, 152:477-486.
50. Gao YJ, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu ZZ, Park JY, Lind AL,
Ma Q, Ji RR: JNK-induced MCP-1 production in spinal cord astrocytes
contributes to central sensitization and neuropathic pain. J Neurosci
2009, 29:4096-4108.
51. Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, Wanibuchi F,
Yamaguchi T: Allodynia and hyperalgesia in adjuvant-induced arthritic
rats: time course of progression and efficacy of analgesics. J Pharmacol
Exp Ther 2003, 306:490-497.
52. Bertorelli R, Corradini L, Rafiq K, Tupper J, Calo G, Ongini E: Nociceptin and
the ORL-1 ligand [Phe1psi (CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-
opioid effects in the Freund’s adjuvant-induced arthritic rat model of
chronic pain. Br J Pharmacol 1999, 128:1252-1258.
53. Burgess GM, Perkins MN, Rang HP, Campbell EA, Brown MC, McIntyre P,
Urban L, Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Wrigglesworth R,
Lee W, Davis C, Phagoo SB, Davis AJ, Phillips E, Drake GS, Hughes GA,
Dunstan A, Bloomfield GC: Bradyzide, a potent non-peptide B(2)
bradykinin receptor antagonist with long-lasting oral activity in animal
models of inflammatory hyperalgesia. Br J Pharmacol 2000, 129:77-86.
54. Gao YJ, Xu ZZ, Liu YC, Wen YR, Decosterd I, Ji RR: The c-Jun N-terminal
kinase 1 (JNK1) in spinal astrocytes is required for the maintenance of
bilateral mechanical allodynia under a persistent inflammatory pain
condition. Pain 2010, 148:309-319.
55. Schaible HG, Schmelz M, Tegeder I: Pathophysiology and treatment of
pain in joint disease. Adv Drug Deliv Rev 2006, 58:323-342.
56. Dev R, Srivastava PK, Iyer JP, Dastidar SG, Ray A: Therapeutic potential of
matrix metalloprotease inhibitors in neuropathic pain. Expert Opin Investig
Drugs 2010, 19:455-468.
doi:10.1186/1742-2094-9-36
Cite this article as: Kular et al.: NOV/CCN3 attenuates inflammatory pain
through regulation of matrix metalloproteinases-2 and -9. Journal of
Neuroinflammation 2012 9:36.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kular et al. Journal of Neuroinflammation 2012, 9:36
http://www.jneuroinflammation.com/content/9/1/36
Page 20 of 20